Analysts Anticipate Repligen Co. (NASDAQ:RGEN) Will Announce Quarterly Sales of $183.55 Million

Wall Street analysts predict that Repligen Co. (NASDAQ:RGENGet Rating) will report sales of $183.55 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Repligen’s earnings, with the lowest sales estimate coming in at $171.50 million and the highest estimate coming in at $193.21 million. Repligen posted sales of $142.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.5%. The business is expected to announce its next quarterly earnings report before the market opens on Monday, January 1st.

On average, analysts expect that Repligen will report full year sales of $820.85 million for the current fiscal year, with estimates ranging from $810.00 million to $828.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $946.77 million, with estimates ranging from $894.20 million to $990.50 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Repligen.

Repligen (NASDAQ:RGENGet Rating) last posted its earnings results on Thursday, February 17th. The biotechnology company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.16. The business had revenue of $186.52 million for the quarter, compared to analysts’ expectations of $178.27 million. Repligen had a net margin of 19.13% and a return on equity of 10.58%. The business’s revenue for the quarter was up 71.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 EPS.

Several brokerages have recently weighed in on RGEN. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price objective on the stock. in a research note on Monday, February 21st. SVB Leerink lowered their price objective on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, February 18th. Finally, began coverage on shares of Repligen in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from, the company has a consensus rating of “Buy” and an average price target of $291.63.

In related news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in RGEN. HM Payson & Co. bought a new position in shares of Repligen during the fourth quarter worth $26,000. Confluence Wealth Services Inc. purchased a new stake in Repligen in the 4th quarter worth $27,000. Allworth Financial LP boosted its holdings in shares of Repligen by 51.4% during the 3rd quarter. Allworth Financial LP now owns 106 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 36 shares during the last quarter. Sageworth Trust Co of South Dakota bought a new position in shares of Repligen during the 4th quarter valued at about $46,000. Finally, Assetmark Inc. bought a new position in shares of Repligen during the 3rd quarter valued at about $49,000. Hedge funds and other institutional investors own 86.25% of the company’s stock.

RGEN opened at $148.64 on Tuesday. The stock has a market capitalization of $8.09 billion, a P/E ratio of 66.36 and a beta of 0.90. The company’s 50-day simple moving average is $175.50 and its two-hundred day simple moving average is $220.35. Repligen has a 52-week low of $142.46 and a 52-week high of $327.32.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with's FREE daily email newsletter.